Clinical trials: Invasive Mold Disease
Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia
Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment
The study aims to evaluate the occurrence, mortality, and risk factors for invasive mold infections (IMI) in children treated with chemotherapy for acute leukemia in Denmark.
- Trial name
- NCT05774990
- Where
- Denmark
- Volunteers
- 621 people
- Sponsor
- University of Southern Denmark
Mucormycosis; Pulmonary (Etiology)
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
Pulmonary mucormycosis is a serious illness with high morbidity and mortality (approximately 57%). Surgery and antifungal therapy are central in the management of mucormycosis.
- Trial name
- NCT05468372
- Testing
- Posaconazole 600 mg followed by posaconazole 300 mg once daily, Liposomal Amphotericin B
- Where
- India
- Volunteers
- 82 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Fusariosis, Onychomycosis
Anti-mold Azole in the Prophylaxis for Invasive Fusariosis
Patients admitted for autologous or allogeneic hematopoietic cell transplantation, induction-remission chemotherapy for acute myeloid leukemia, myelodysplasia or acute lymphoid leukemia, or to receive immunosuppressive therapy…
- Trial name
- Fusarproph (NCT02714504)
- Testing
- Voriconazole or posaconazole
- Where
- Brazil
- Volunteers
- 239 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Invasive Fungal Infection
Registry of Patients Treated With Systemic Mold-Active Triazoles
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI).
- Trial name
- NCT03066011
- Testing
- Isavuconazonium sulfate, Voriconazole, Posaconazole
- Where
- 56 sites in United States
- Volunteers
- 2,015 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Invasive Mold Diseases
Safety and Efficacy of Liposomal Amphotericin B for Patients With Invasive Mold Diseases in Liver Transplant Recipients
Invasive mold diseases (IMD) carry extremely high mortality rates in liver transplant recipients (aspergillosis prevalence ~1.8%, mortality 60%-90%; mucormycosis prevalence ~2%, mortality 38%-95%).
- Trial name
- NCT07725874
- Testing
- AmBisome (Amphotericin B) Liposome
- Volunteers
- 60 people
- Sponsor
- Beijing Friendship Hospital
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Fungal Infection
A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing
This is a prospective, multicenter, randomized trial to study therapeutic drug monitoring (TDM) of voriconazole among patients with an invasive mould infection (IMI).
- Trial name
- VoriTDM (NCT01416025)
- Testing
- Prospective TDM Arm
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Johns Hopkins University
Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
This study will establish a non-invasive diagnostic approach and evaluate clinical outcomes for children at high-risk for pulmonary invasive fungal infection (PIFI).
- Trial name
- DOMINIC (NCT03827694)
- Testing
- Non-Invasive Testing for PIFI
- Where
- 33 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Arkansas Children's Hospital Research Institute